SageView Advisory Group
CRVS icon

SageView Advisory Group’s Corvus Pharmaceuticals CRVS Stock Holding History

SageView Advisory Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30
Closed -$231 – 1003
2025
Q4 		$231 Buy
+30
New +$237 ﹤0.01% 2506

Other funds holding CRVS

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SageView Advisory Group's CRVS Position: Q1 2026 in Review

SageView Advisory Group sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 30 shares — an estimated $231 sold.

SageView Advisory Group first reported a position in CRVS in Q4 2025 and held it in 1 quarter. The position peaked at $231 in Q4 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • SageView Advisory Group reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 30 Corvus Pharmaceuticals shares in Q1 2026, an estimated $231.
  • SageView Advisory Group first reported a position in Corvus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Corvus Pharmaceuticals position peaked at $231 in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.